购物车
- 全部删除
- 您的购物车当前为空
Tolebrutinib (PRN2246) 是一种选择性、有效的、具有口服活性、可透过血脑屏障的布鲁顿氏酪氨酸激酶抑制剂,能够作用于 Ramos B 细胞 (IC50:0.4 nM)、HMC 小胶质细胞 (IC50:0.7 nM)。它对中枢神经系统免疫具有功效。它可用于多发性硬化症的研究。
为众多的药物研发团队赋能,
让新药发现更简单!
Tolebrutinib (PRN2246) 是一种选择性、有效的、具有口服活性、可透过血脑屏障的布鲁顿氏酪氨酸激酶抑制剂,能够作用于 Ramos B 细胞 (IC50:0.4 nM)、HMC 小胶质细胞 (IC50:0.7 nM)。它对中枢神经系统免疫具有功效。它可用于多发性硬化症的研究。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 247 | 现货 | |
5 mg | ¥ 689 | 现货 | |
10 mg | ¥ 1,160 | 现货 | |
25 mg | ¥ 1,990 | 现货 | |
50 mg | ¥ 2,960 | 现货 | |
100 mg | ¥ 4,850 | 现货 | |
200 mg | ¥ 6,730 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 690 | 现货 |
产品描述 | Tolebrutinib (PRN2246) is a potent, selective, orally active and brain-penetrant Bruton tyrosine kinase (BTK) inhibitor(IC50s of 0.4 and 0.7 nM in Ramos B cells and in HMC microglia cells, respectively). It exhibits efficacy in central nervous system immunity. Tolebrutinib can be used for the research of multiple sclerosis (MS). |
靶点活性 | BTK:0.4 nM (in Ramos B cells) , BTK:0.7 nM(in HMC microglia cell) |
体外活性 | PRN2246 inhibits microglial FcγR activation through durable occupancy of BTK, with an IC50 of 157 nM.?PRN2246 blocks the BCR-mediated activation (IC50=10 nM) and Fc receptor activation (IC50=166 and 9.6 nM for FcεR and FcγR, repectively) of immune cells[1]. |
体内活性 | PRN2246 produces dose-dependent protection from in myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE) model[1] |
别名 | SAR442168, PRN2246 |
分子量 | 455.51 |
分子式 | C26H25N5O3 |
CAS No. | 1971920-73-6 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 100 mg/mL (219.53 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.